login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

“We will see steady progress in percutaneous mitral valve therapy over the next couple of years”


Thursday, 15 Mar 2012 11:18
Ted Feldman
Ted Feldman

Catheter-based mitral valve repair with MitraClip is the best-studied type of percutaneous mitral valve therapy, said Ted Feldman, Evanston Hospital, NorthShore University Health System, Evanston, USA, at the International Symposium on Endovascular Therapy (ISET) in Miami.


The EVEREST II (Endovascular valve edge-to-edge repair study) study assessed the safety and effectiveness of the MitraClip device (Abbott Vascular) in patients with significant mitral regurgitation at high risk of surgical mortality rate. The study, published by Feldman et al (N Engl J Med 2011;364:1395–1406), concluded that although percutaneous repair with the MitraClip device “was less effective at reducing mitral regurgitation than conventional surgery, the procedure was associated with superior safety and similar improvements in clinical outcomes.”


A substudy was done on high risk patients. An analysis of the acute and 12-month results of 78 patients showed that the survival rate at one year was 76% in the high risk study and 55% in the concurrent comparator group (p=0.047) of screened concurrently but not enrolled patients.


Feldman showed delegates research behind various other mitral valve devices, including the Carillon Mitral Contour System (Cardiac Dimensions). The TITAN trial showed 40% reduction in mitral regurgitation, improvements in reverse remodeling and functional improvement in patients implanted with the device. “Outcomes in terms of reduced mitral regurgitation and improved chamber function are notable,” he said.


The future of the field may be direct annuloplasty using different delivery devices, including the transventricular approach, which is used in the Mitralign Percutaneous Annuloplasty System or the Guided Delivery System, Feldman said. In this transcatheter procedure, surgical implants are placed directly into the mitral annulus and tensioned through a catheter to reduce the annular circumference, thus mimicking the surgical techniques.


One of the most interesting devices is the Myocor Surgical Coapsys System, he said. This is a novel approach that uses a cathether passed through the left ventricle to reshape the left ventricle and reduce the mitral regurgitation. In the RESTOR-MV (Randomized evaluation of a surgical treatment for off-pump repair of the mitral valve) trial, the system was shown to reduce mortality. The investigators concluded that “patients with functional mitral regurgitation requiring revascularisation treated with ventricular reshaping rather than standard surgery had improved survival and a significant decrease in major adverse outcomes. This trial validates the concept of the ventricular reshaping strategy in this subset of patients with heart failure.”


Another innovation in the field is transcatheter mitral valve replacement, Feldman noted. This approach will use a catheter to deliver a new mitral valve. The major challenge for valve replacement is anchoring of the new valve in the native annulus.


“There is a lot happening in the field, and we will see steady progress over the next couple of years,” Feldman concluded.




Add New Comment

Related Items


Most popular


Combined mitral valve repair and CABG do not provide additional benefits
Friday, 28 Nov 2014
The combination of coronary artery bypass grafting (CABG) and mitral valve repair is not associated with additional benefits compared with CABG alone in patients with multivessel disease and moderate ... Combined mitral valve repair and CABG do not provide additional benefits

REVA implants first patients with Fantom scaffold
Thursday, 04 Dec 2014
REVA Medical has initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold. REVA implants first patients with Fantom scaffold

Too early to say that renal denervation is a failed therapy
Thursday, 04 Dec 2014
In a new consensus statement, the Joint UK Societies claim that the negative results of SYMPLICITY HTN-3 should not be used as a “rationale for abandoning” renal denervation as a “novel therapeutic ... Too early to say that renal denervation is a failed therapy

Features


ICI meeting is a “fruitful ground for new developments” in interventional cardiology
Tuesday, 13 Jan 2015
Rafael Bayer, co-chairman of the Innovation in Cardiovascular Intervention (ICI) meeting (14–16 December 2014, Tel Aviv, Israel), speaks to Cardiovascular News about the event’s unique features. ICI meeting is a “fruitful ground for new developments” in interventional cardiology

Performing TAVI in a hybrid operating room
Wednesday, 10 Dec 2014
Daniel O’ Hair believes hybrid ORs may provide distinct advantages for complex TAVI cases. He speaks to Cardiovascular News about his experience of performing TAVI in a hybrid OR. Performing TAVI in a hybrid operating room

Profiles


Sunil Rao
Thursday, 23 Oct 2014
Sunil Rao speaks to Cardiovascular News about his career highlights, including his research into ... Sunil Rao

Azeem Latib
Wednesday, 24 Sep 2014
Azeem Latib (senior interventional cardiologist, San Raffaele Hospital and EMO-GVM Centro Cuore C... Azeem Latib

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions